Skip to the answer

Scopolamine Transdermal Patch

Scopolamine transdermal patch is an anticholinergic medication used to prevent nausea and vomiting from motion sickness and from surgery and anesthesia.

Brand names Transderm ScopScopolamine Transdermal System
Drug class Anticholinergic
Rx Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 17 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 6, 2026
Scopolamine Transdermal Patch at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

The scopolamine patch is an anticholinergic, meaning it blocks certain nerve signals, here the ones running from the inner ear's balance centers to the brain's vomiting center, and it prevents nausea and vomiting from motion sickness or after surgery and anesthesia in adults; a familiar standby since about 1979, it is available generically. Most people tolerate it well, though dry mouth is very common, and drowsiness and blurry vision come next. Watch closely for confusion, hallucinations or agitation, especially in older adults, and take the patch off and get help if they appear. Because it cuts sweating, it can also cause dangerous, even fatal, overheating in hot weather.

Clinical pearls

  • Put it on clean, hairless skin behind one ear at least 4 hours before travel, then wash your hands with soap and water.
  • Take it off before any MRI scan, because its metallic layer can burn the skin.
  • Dizziness, nausea or headache a day or more after removal can be withdrawal, not your motion sickness returning.
  • Report eye pain, halos around lights or trouble passing urine right away, since scopolamine can trigger a sudden glaucoma attack.
How you get itPrescription only
Comes asSkin patch
Earliest FDA record1979
Companies listing it with the FDA12
FDA label last updatedJun 10, 2025
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Scopolamine Transdermal Patch, written from its FDA label.

What Scopolamine Transdermal Patch is used for

▾

Scopolamine transdermal patches are approved for adults to prevent two types of nausea and vomiting:

  • Motion sickness: Scopolamine Transdermal System and Transderm Scōp are used to prevent the nausea and vomiting that comes with travel by car, boat, plane, or other movement.
  • Post-operative nausea and vomiting (PONV): Transderm Scōp is applied before surgery to prevent nausea and vomiting related to anesthesia, opioid pain medicines, and the surgical procedure itself — for surgeries other than cesarean section.

How Scopolamine Transdermal Patch works

▾

Scopolamine is an anticholinergic — it blocks the action of a chemical messenger called acetylcholine in the nervous system. Most importantly for nausea, it interrupts the nerve signals traveling from the vestibular system (your inner ear's balance center) to the brain's vomiting center. By blocking those signals, the brain doesn't receive the trigger to make you feel or be sick. The patch format slowly releases the medicine through the skin into the bloodstream over three days, providing steady, long-lasting coverage without needing to swallow a pill.

Scopolamine Transdermal Patch dosage

▾

The patch is applied to the clean, dry, hairless skin behind one ear. For motion sickness, apply it at least 4 hours before protection is needed; one patch lasts up to 3 days. For longer trips, remove the first patch and apply a new one behind the other ear. For surgery prevention, Transderm Scōp is applied the evening before the procedure and removed 24 hours after surgery. Only wear one patch at a time, never cut it, and always follow your prescriber's specific instructions.

Dosing details from the FDA-approved label

From the Scopolamine Transdermal Patch prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Motion Sickness
    • Apply one TRANSDERM SCŌP transdermal system to the hairless area behind one ear at least 4 hours before the antiemetic effect is required – for use up to 3 days
    • If therapy is required for longer than 3 days, remove the first transdermal system and apply a new TRANSDERM SCŌP transdermal system behind the other ear
    • Each system delivers approximately 1 mg of scopolamine over 3 days; only wear one transdermal system at a time.
  • PONV (surgeries other than cesarean section)
    • Apply one TRANSDERM SCŌP transdermal system the evening before scheduled surgery
    • Remove the transdermal system 24 hours following surgery
    • Apply behind the ear; only wear one transdermal system at a time.
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Application and Removal ( 2.1 ): • Each TRANSDERM SCŌP transdermal system delivers 1 mg of scopolamine over 3 days. • Only wear one transdermal system at a time. • Do not cut the transdermal system. • Wash hands thoroughly with soap and water after application. • Avoid touching or applying pressure to the transdermal system once applied. • Upon removal, fold used transdermal system in half with sticky side together, discard to prevent accidental contact or ingestion, and wash the hands and application site with soap and water. Recommended Dosage : • Motion Sickness : Apply one transdermal system to the hairless area behind one ear at least 4 hours before antiemetic effect is required for use up to 3 days. If therapy for more than 3 days is required, remove the first transdermal system and apply a new transdermal system behind the other ear. ( 2.2 ) • PONV : For surgeries other than cesarean section, apply one transdermal system behind the ear the evening before surgery and remove 24 hours following surgery. ( 2.2 ) 2.1 Important Application and Removal Instructions • Each TRANSDERM SCŌP transdermal system is formulated to deliver in vivo approximately 1 mg of scopolamine over 3 days. • Only wear one transdermal system at any time. • Do not cut the transdermal system. • Apply the transdermal system to the skin in the postauricular area (hairless area behind one ear). • After the transdermal system is applied on the dry skin behind the ear, wash hands thoroughly with soap and water and dry hands [see Warnings and Precautions ( 5.7 )] . • If the transdermal system becomes displaced, discard the transdermal system, and apply a new transdermal system on the hairless area behind the other ear. • Once the transdermal system has been affixed, avoid touching or applying pressure to the transdermal system while it is being worn, since pressure exerted on it may cause scopolamine to ooze out at the edge. • Upon removal, fold the used transdermal system in half with the sticky side together, and discard in household trash in a manner that prevents accidental contact or ingestion by children, pets or others. • Wash the hands and application site with soap and water after transdermal system removal [see Warnings and Precautions ( 5.7 )] .

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Scopolamine Transdermal Patch side effects

▾

The most common side effects vary a little depending on the reason for use:

Common side effects

  • Dry mouth (very common, especially for motion sickness)
  • Drowsiness or sleepiness
  • Blurred vision
  • Dilated pupils (eyes more sensitive to light)
  • Dizziness
  • Confusion or disorientation
  • Skin irritation, itching, or redness at the patch site
  • For PONV prevention: dry mouth, dizziness, sleepiness, agitation, visual changes, confusion, dilated pupils, and sore throat
  • At the skin site: redness, itching, blistering, or rash under the patch
  • Dry eyes, eyelid irritation, vertigo, or difficulty urinating have also been reported

When to get medical help

  • Call your doctor right away if you have eye pain, blurred vision, or see halos — these can be signs of acute angle closure glaucoma (a sudden, dangerous rise in eye pressure)
  • Seek medical help if you experience hallucinations, paranoia, agitation, or other unusual psychiatric symptoms
  • Remove the patch and contact a healthcare provider if your body temperature rises or you stop sweating in warm conditions — this can lead to dangerous overheating
  • Get medical attention if you have difficulty urinating or notice signs of urinary retention
  • Call your doctor if you develop seizures or seizure-like activity
  • After removing the patch, watch for withdrawal symptoms such as severe dizziness, nausea, headache, or confusion — seek help if symptoms are severe
  • Remove the patch before any MRI scan to prevent skin burns at the application site

Seek immediate help for hallucinations, severe confusion, eye pain, high fever without sweating, or difficulty urinating — these are signs of serious reactions that need prompt attention.

Scopolamine Transdermal Patch warnings and precautions

▾
  • Eye pressure (angle closure glaucoma): Scopolamine can dilate pupils and raise pressure inside the eye, triggering a sudden, painful eye emergency. If you have any type of glaucoma, tell your doctor before using this patch.
  • Psychiatric and cognitive effects: Hallucinations, paranoia, agitation, confusion, and even seizures have been reported. Older adults are at higher risk. Remove the patch and seek help if these occur.
  • Dangerous overheating (hyperthermia): The patch reduces sweating, which can let your body temperature climb to dangerous levels — especially in hot weather. Fatal cases have occurred. Remove the patch and contact a provider if you stop sweating or feel overheated.
  • Withdrawal after removal: After several days of use, removing the patch can cause dizziness, nausea, headache, sweating, and confusion starting 24 hours or more after removal. These symptoms can be severe.
  • MRI burns: The patch contains a metallic layer. Always remove it before an MRI scan to prevent skin burns.
  • Urinary retention: Scopolamine can make it hard to urinate. Stop using the patch and call your doctor if you have difficulty urinating.
  • Pregnancy: Avoid use in severe preeclampsia — eclamptic seizures have been reported in pregnant women given scopolamine in that setting.

Scopolamine Transdermal Patch interactions

▾

Several types of medicines and substances can interact with the scopolamine patch and increase your risk of side effects:

  • Sedatives, sleep aids, opioids, and anti-anxiety drugs: Can dramatically increase drowsiness and disorientation — use together with caution or avoid if possible.
  • Alcohol: Worsens CNS effects like drowsiness and impaired coordination.
  • Other anticholinergic drugs (certain antihistamines, tricyclic antidepressants, muscle relaxants, meclizine, other belladonna alkaloids): Stacking anticholinergic effects raises the risk of confusion, urinary retention, overheating, and bowel slowdown.
  • Oral medicines absorbed in the stomach: Scopolamine slows the stomach, which can alter how quickly other oral drugs are absorbed — especially important for medicines with a narrow margin between a working dose and a harmful one.
  • Gastric secretion testing: Remove the patch at least 10 days before this type of test, as scopolamine will skew the results.

Interactions listed in the FDA-approved label

From the Scopolamine Transdermal Patch prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Drugs causing CNS adverse reactions of drowsiness, dizziness or disorientation (e.g., sedatives, hypnotics, opiates, anxiolytics and alcohol) or having anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants): Concurrent use may potentiate the effects of scopolamine transdermal system. Either scopolamine transdermal system or the interacting drug should be chosen, depending on the importance of the drug to the patient. If the interacting drug cannot be avoided, monitor patients for CNS adverse reactions.
  • Anticholinergic drugs: Concomitant use with other drugs having anticholinergic properties may increase the risk of CNS adverse reactions, intestinal obstruction and/or urinary retention. Consider more frequent monitoring during treatment with scopolamine transdermal system in patients receiving anticholinergic drugs.
  • Oral drugs absorbed in the stomach: Scopolamine transdermal system, as an anticholinergic, may delay gastric and upper gastrointestinal motility and, therefore, the rate of absorption of other orally administered drugs. Monitor patients for modified therapeutic effect of concomitant orally administered drugs with a narrow therapeutic index.
  • Gastric secretion test: Scopolamine will interfere with the gastric secretion test. Discontinue scopolamine transdermal system 10 days prior to testing.
Read the label’s full interactions text

7 DRUG INTERACTIONS • Drugs Causing Central Nervous System (CNS) Adverse Reactions : Monitor patients for CNS adverse reactions (drowsiness, dizziness or disorientations). ( 7.1 ) • Anticholinergic Drugs : Consider more frequent monitoring during treatment in patients receiving other anticholinergic drugs. ( 7.2 ) • Oral Drugs Absorbed in the Stomach : Monitor for increased or decreased therapeutic effect of the oral drug. ( 7.3 ) • Interaction with Gastric Secretion Test : Discontinue use of scopolamine transdermal system 10 days prior to testing. ( 7.4 ) 7.1 Drugs Causing Central Nervous System (CNS) Adverse Reactions The concurrent use of scopolamine transdermal system with other drugs that cause CNS adverse reactions of drowsiness, dizziness or disorientation (e.g., sedatives, hypnotics, opiates, anxiolytics and alcohol) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may potentiate the effects of scopolamine transdermal system [see Warnings and Precautions ( 5.2 )] . Either scopolamine transdermal system or the interacting drug should be chosen, depending on the importance of the drug to the patient. If the interacting drug cannot be avoided, monitor patients for CNS adverse reactions. 7.2 Anticholinergic Drugs Concomitant use of scopolamine with other drugs having anticholinergic properties may increase the risk of CNS adverse reactions [see Drug Interactions ( 7.1 )], intestinal obstruction and/or urinary retention. Consider more frequent monitoring during treatment with scopolamine transdermal system in patients receiving anticholinergic drugs [see Warnings and Precautions ( 5.2 , 5.4 )] . 7.3 Oral Drugs Absorbed in the Stomach Scopolamine transdermal system, as an anticholinergic, may delay gastric and upper gastrointestinal motility and, therefore, the rate of absorption of other orally administered drugs.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before taking Scopolamine Transdermal Patch

▾
  • Angle closure glaucoma: Do not use — scopolamine can trigger a dangerous spike in eye pressure.
  • Allergy to scopolamine or belladonna alkaloids: Do not use if you've had a reaction to this family of medicines.
  • Open-angle glaucoma: Use with caution; your eye pressure should be monitored.
  • Seizure history: Talk to your doctor — scopolamine may lower the seizure threshold.
  • Prostate enlargement or bladder problems: Higher risk of urinary retention; monitor carefully.
  • Suspected intestinal blockage: Use with caution and closer monitoring.
  • Pregnancy: Scopolamine crosses the placenta. Avoid in severe preeclampsia due to seizure risk.
  • Breastfeeding: Scopolamine passes into breast milk; discuss risks and benefits with your doctor.
  • Children: Not approved for pediatric use; serious reactions including hallucinations, hyperthermia, and a fatal case have been reported in children.
  • Older adults (65+): Higher risk of confusion, hallucinations, dizziness, and overheating — closer monitoring is recommended.
  • Kidney or liver impairment: Increased risk of CNS side effects; more frequent monitoring is advised.

Scopolamine Transdermal Patch overdose

▾

Too much scopolamine — for example from wearing multiple patches at once or from a patch being swallowed — can cause serious anticholinergic toxicity. Signs include rapid heart rate, confusion, hallucinations, seizures, high body temperature, urinary retention, dry flushed skin, and vision disturbances. If this happens, remove all patches immediately and call Poison Control at 1-800-222-1222 or go to an emergency room.

What Scopolamine Transdermal Patch does in the body

▾

Scopolamine works by blocking muscarinic receptors — the docking sites that the nerve chemical acetylcholine normally binds to — in the parasympathetic nervous system and in the brain. By doing so, it can reduce saliva and sweat production, slow gut movement, dilate the pupils, increase heart rate, cause drowsiness, and suppress the signals that trigger vomiting. These widespread effects explain both its therapeutic benefits and its potential side effects.

How your body processes Scopolamine Transdermal Patch

▾

After the patch is applied behind the ear, scopolamine begins entering the bloodstream within about 4 hours, with peak blood levels reached on average within 24 hours. The patch is designed to release medicine steadily over 3 days. Once the patch is removed, some scopolamine that has been absorbed into the skin continues to enter the bloodstream, which is why effects — and sometimes withdrawal symptoms — can persist after removal. The drug is broken down in the body and eliminated mainly through the urine, with a half-life (the time it takes blood levels to fall by half) of about 9.5 hours after the patch comes off.

How to store Scopolamine Transdermal Patch

▾

Store upright at 20° to 25°C (68° to 77°F) . Store pouch(es) in an upright position.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

51

Supplements & herbs that interact with Scopolamine Transdermal Patch

51 supplements and herbal products have documented interactions with Scopolamine Transdermal Patch in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 4
  • Moderate · 34
  • Minor · 13
Every supplement checked against Scopolamine Transdermal Patch — ranked by severity The full interaction hub: 4 major · 34 moderate · 13 minor · every one linked to its full report. Check Scopolamine Transdermal Patch against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Scopolamine Transdermal Patch: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Scopolamine Transdermal Patch — the kind of thing our pharmacy team would talk through with you at the counter.

Where exactly do I put the patch, and does it matter which side?

▾
Apply it to the hairless skin directly behind one ear — that flat area just behind the earlobe. Either side works fine. The key is that the skin is clean, dry, and hair-free so the patch sticks well and the medicine absorbs evenly. If you need more than 3 days of coverage, remove the first patch and place a fresh one behind the other ear.

How soon before a trip should I put the patch on?

▾
Put it on at least 4 hours before you need it to be working — so if you're boarding a cruise ship in the morning, apply it the night before. The patch takes several hours to build up enough medicine in your system to prevent nausea, so early application is really important. Don't wait until you're already feeling queasy.

My mouth feels really dry and I'm a bit drowsy — is that normal?

▾
Yes, those are the most common side effects and they're expected with this medication. Dry mouth happens in a large portion of people using it for motion sickness, and some drowsiness is also common. Staying hydrated and sucking on sugar-free candy or gum can help with the dry mouth. The drowsiness is why you should be careful about driving or doing anything that requires sharp focus until you know how the patch affects you.

Can the patch affect my eyes?

▾
It can, especially if you accidentally get scopolamine on your fingers and then touch your eye. That can cause your pupil to dilate and your vision to go blurry temporarily. This is why washing your hands thoroughly right after applying or removing the patch is so important. If you ever experience eye pain, a sudden change in vision, or see halos around lights along with a red eye, remove the patch and get medical help right away — that could be a serious eye pressure problem called acute angle closure glaucoma.

Is it safe to drink alcohol while wearing the patch?

▾
It's best to avoid alcohol while using this patch. Both scopolamine and alcohol affect the brain and nervous system, and combining them can make drowsiness, dizziness, and confusion significantly worse. The same goes for sleep aids, anti-anxiety medicines, and opioid pain relievers — mixing any of these with the patch increases the risk of sedation and impairment.

What happens when I take the patch off — will I feel sick?

▾
Some people do experience withdrawal-type symptoms after removing the patch, usually starting 24 hours or more after it comes off. These can include dizziness, nausea, headache, sweating, and sometimes confusion. It's more common after several days of use. If your symptoms are mild, they typically pass on their own. But if they're severe — especially severe confusion or vomiting — contact your doctor. It's worth knowing that even after removal, some medicine continues to absorb from the skin for a while, so effects don't stop immediately.

Is Scopolamine Transdermal Patch available over the counter?

▾
No. Scopolamine Transdermal Patch is a prescription medicine: every Scopolamine Transdermal Patch product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Scopolamine Transdermal Patch first available?

▾
The earliest FDA record we hold for Scopolamine Transdermal Patch is from 1979: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Scopolamine Transdermal Patch was first used.

Who makes Scopolamine Transdermal Patch?

▾
12 companies currently list Scopolamine Transdermal Patch products in the FDA's NDC Directory, including Bryant Ranch Prepack, A-S Medication Solutions, Actavis Pharma, Inc.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Scopolamine Transdermal Patch on HelloPharmacist

Detailed data & references for Scopolamine Transdermal Patch Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Scopolamine Transdermal Patch forms and strengths (how it comes)

Scopolamine Transdermal Patch is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Scopolamine Transdermal Patch inactive ingredients by manufacturer.

Skin patch

Through the skin
Brands Scopolamine Transdermal System Transderm Scop
How this form is used
What it may be used for
  • Transderm Scōp is used to prevent nausea and vomiting from motion sickness in adults
  • Transderm Scōp is used to prevent post-operative nausea and vomiting (PONV) following surgery and anesthesia in adults
Important instructions
  • Transderm Scōp: apply one patch to the hairless skin behind one ear at least 4 hours before antiemetic effect is needed for motion sickness; replace with a new patch behind the other ear if more than 3 days of coverage is needed
  • Transderm Scōp: for surgery (other than cesarean section), apply one patch the evening before the scheduled procedure and remove it 24 hours after surgery
  • Wear only one Transderm Scōp patch at a time; do not cut the patch
  • Wash hands thoroughly with soap and water immediately after applying or removing the Transderm Scōp patch, and wash the skin at the application site after removal
Available strengths 4 strengths
23 FDA-listed product records ⓘ

Scopolamine Transdermal Patch on the U.S. market: products, makers and brands

How Scopolamine Transdermal Patch appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

12 companies list 17 Scopolamine Transdermal Patch product records with the FDA, mostly as skin patch; the earliest marketing or approval year on record is 1979. Brand names on the directory include Transderm Scop, Scopolamine Transdermal System; the rest are generics.

1
Dose forms ⓘ
12
Labelers (makers, repackagers, distributors)
3
Brand names
17
FDA-listed product records ⓘ
1979
Earliest FDA record ⓘ
Bryant Ranch Prepack29%
A-S Medication Solutions12%
Actavis Pharma, Inc.6%
Amneal Pharmaceuticals NY LLC6%
Baxter Healthcare Corporation6%
Ingenus Pharmaceuticals, LLC6%
Other makers35%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Scopolamine Transdermal Patch is used (Medicaid data)

A general measure of how commonly Scopolamine Transdermal Patch is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Scopolamine Transdermal Patch is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

143,028
Medicaid prescriptions filled (Q1–Q4 2025)
$6.7M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Scopolamine Transdermal Patch prescribed? Of the 1,601 medications we measure, Scopolamine Transdermal Patch ranks #443 by Medicaid prescriptions — more than 72% of them.

Where Scopolamine Transdermal Patch ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Scopolamine Transdermal Patch product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

72 HR scopolamine 0.0139 MG/HR Transdermal System

143,028 Medicaid prescriptions (Q1–Q4 2025) 100% of Scopolamine Transdermal Patch prescriptions shown $6.7M gross reimbursement (before rebates) ≈ $47 per prescription (gross)

Summed across the 20 of 60 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 226552

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Scopolamine Transdermal Patch, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 20 of 60 listed Scopolamine Transdermal Patch NDCs with Medicaid activity.

Compare Scopolamine Transdermal Patch products

A representative set of FDA-listed product records for Scopolamine Transdermal Patch — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 17 of 17 products — FDA National Drug Code Directory. For the full list, search the NDC directory →

Scopolamine Transdermal Patch recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list one Scopolamine recall since July 2021. It is no longer listed as ongoing. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.

Class II Apr 13, 2022 · Terminated · Mckesson Medical-Surgical Inc. Corporate Office
cGMP deviations: Temperature abuse
  • Transderm Scop (scopolamine) Transdermanl System, 1 mg/ 3 days, 10 (patches) transdermal Systems Multipack, Rx only, MFG: Baxter Healthcare Corp, NDC 10019-553-03 Lots: McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that i… FDA record D-1083-2022 →

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Scopolamine Transdermal Patch RxCUI 9601 4 dose forms · 9 strengths
  1. Dose form (SCDF) Injectable Solution RxCUI 373830 No current FDA listing
    Clinical drug / strength (SCD) 0.4 MG/ML RxCUI 198207 0.6 MG/ML RxCUI 245350
  2. Dose form (SCDF) Ophthalmic Solution RxCUI 377414 No current FDA listing
    Clinical drug / strength (SCD) 1.25 MG/ML RxCUI 106807 2.5 MG/ML RxCUI 312910 5 MG/ML RxCUI 106808
  3. Dose form (SCDF) Oral Tablet RxCUI 373831 No current FDA listing
    Clinical drug / strength (SCD) 0.15 MG RxCUI 250537 0.3 MG RxCUI 250536 0.4 MG RxCUI 200059
  4. Dose form (SCDF) Transdermal System RxCUI 1806049 In current FDA listings
    Clinical drug / strength (SCD) 72 HR scopolamine 0.0139 MG/HR RxCUI 226552

Look up RxCUI 9601 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Scopolamine Transdermal Patch costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Patch, Extended Release · Transdermal SCOPOLAMINE 1 mg/3d $11.02 each NDC details & price history
Patch, Extended Release · Transdermal 1.5 mg $4.34 each NDC details & price history
Patch, Extended Release · Transdermal 1 mg $4.34 each NDC details & price history
Patch · Transdermal 1 mg/3d $4.34 each NDC details & price history
Patch · Transdermal SCOPOLAMINE 1 mg/3d $4.34 each NDC details & price history
System · Transdermal SCOPOLAMINE 1 mg/3d $4.34 each NDC details & price history
System · Transdermal 1 mg/3d $4.34 each NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Scopolamine Transdermal Patch brand names

Scopolamine Transdermal Patch is sold under 2 brand names in the FDA directory — Transderm Scop, Scopolamine Transdermal System. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Transderm Scop Scopolamine Transdermal System

Who makes Scopolamine Transdermal Patch: manufacturers and labelers

12 companies list Scopolamine Transdermal Patch products with the FDA. By number of product records, the largest are Bryant Ranch Prepack, A-S Medication Solutions, Actavis Pharma, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Bryant Ranch Prepack 5 A-S Medication Solutions 2 Actavis Pharma, Inc. 1 Amneal Pharmaceuticals NY LLC 1 Baxter Healthcare Corporation 1 Ingenus Pharmaceuticals, LLC 1 Mylan Pharmaceuticals Inc. 1 NuCare Pharmaceuticals, Inc. 1 Padagis Israel Pharmaceuticals Ltd 1 Rhodes Pharmaceuticals LLC 1 Zydus Lifesciences Limited 1 Zydus Pharmaceuticals USA Inc. 1

Scopolamine Transdermal Patch drug class (RxNorm)

Scopolamine Transdermal Patch belongs to the Anticholinergic class.

Pharmacologic class Anticholinergic
Drug family (ATC) Other antiemetics, Other hypnotics and sedatives, Anticholinergics
How it works Cholinergic Antagonists

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Scopolamine Transdermal Patch page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Jun 10, 2025
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Scopolamine Transdermal Patch.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Scopolamine Transdermal Patch after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
17
Finished products in the current FDA directory
17
Companies listing them (makers, repackagers, distributors)
12
FDA labeler codes behind them ⓘ
13
Linked representative label ⓘ
Baxter Healthcare Corporation
Linked label effective
Jun 10, 2025
Composite sections available
22
Linked SPL Set ID
b877a694-a1d0-4280-937a-a06820b12a88
Linked SPL Document ID
b29f6fe1-c232-49ac-914b-29c31ab8c73d
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Baxter Healthcare Corporation is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →